The year of the bispecific in oncology and beyond

Andrew Marshall
Biopharma Dealmakers · Springer Nature · 2025-12-01 · DOI: 10.1038/d43747-025-00111-4

Abstract

Biopharma Dealmakers, Published online: 01 December 2025; doi:10.1038/d43747-025-00111-4 Bispecific and multispecific antibodies are gaining momentum in oncology research. They accounted for a quarter of the top 20 highest-grossing deals in the year to date, with many transactions focusing on Chinese assets.

Read at publisher →

Similar articles